Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank)

被引:4
|
作者
Charoenpong, Prangthip [1 ,2 ,3 ]
Dhillon, Navneet [4 ]
Murnane, Kevin [2 ,3 ,5 ,6 ]
Goeders, Nicholas [2 ,3 ,5 ,6 ]
Hall, Nicole [5 ]
Keller, Courtney [5 ]
Bhuiyan, Mohammad Alfrad Nobel [2 ,7 ]
Walter, Robert [1 ,2 ,3 ]
机构
[1] Louisiana State Univ Hlth Sci Ctr Shreveport, Div Pulm & Crit Care, Internal Med, Shreveport, LA 71103 USA
[2] Louisiana State Univ, Hlth Sci Ctr Shreveport, Ctr Cardiovasc Dis & Sci, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Louisiana Addit Res Ctr, Hlth Sci Ctr Shreveport, Shreveport, LA 71103 USA
[4] Univ Kansas, Dept Internal Med, Internal Med Pulm & Crit Care, Med Ctr, Kansas City, KS USA
[5] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA USA
[6] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Psychiat, Shreveport, LA USA
[7] Louisiana State Univ, Div Clin Informat, Internal Med, Hlth Sci Ctr Shreveport, Shreveport, LA USA
关键词
Drug induced Lung Disease; Primary Pulmonary Hypertension; Rare lung diseases; Clinical Epidemiology; Patient Outcome Assessment; OUTCOMES; INVOLVEMENT; TRANSPORTER;
D O I
10.1136/bmjresp-2023-001917
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
ObjectiveThis study compares the clinical and haemodynamic severity of methamphetamine-associated pulmonary arterial hypertension (MA-PAH) with idiopathic pulmonary arterial hypertension (IPAH) and connective tissue-associated pulmonary arterial hypertension (CTD-PAH). It also examines sex differences in clinical and physiological parameters among those with MA-PAH.DesignThis is a cross-sectional study using clinically derived data from the National Biological Sample and Data Repository for Pulmonary Arterial Hypertension (PAH biobank), a US-based registry, to compare clinical and physiological characteristics between males and females with MA-PAH.PopulationThe analysis included 1830 patients enrolled in the PAH biobank, with a diagnosis of MA-PAH (n=42), IPAH (n=1073), or CTD-PAH (n=715).Main outcome measuresThe study assessed and compared the clinical and haemodynamic parameters of patients with MA-PAH, IPAH and CTD-PAH.ResultsAmong the patients analysed, 42 had MA-PAH, with 69.1% being female. There were no statistically significant differences in functional class among patients with MA-PAH, IPAH and CTD-PAH. The per cent predicted 6-min walk distance (6MWD) was comparable between the three groups. Patients with MA-PAH had similar mean pulmonary artery pressure and pulmonary vascular resistance to patients with IPAH but higher compared with patients with CTD-PAH. Male patients with MA-PAH exhibited a worse functional class and lower per cent predicted 6MWD, but no significant differences in haemodynamic findings were observed between the sexes.ConclusionThere were no differences in haemodynamic between MA-PAH and IPAH but we found that MA-PAH differed from CTD-PAH. The study did not find evidence of sex differences in MA-PAH. Further research is necessary to identify risk factors and underlying mechanisms of MA-PAH, particularly considering the increasing prevalence of methamphetamine use. Such investigations will contribute to the development of effective prevention and treatment strategies for this condition.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Regional Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension (PAH)
    Winkler, T.
    Kohli, P.
    Kelly, V. J.
    Kehl, E. G.
    Kone, M. T.
    Hibbert, K.
    Rodriguez-Lopez, J. M.
    Systrom, D. M.
    Waxman, A. B.
    Venegas, J. G.
    Channick, R. N.
    Harris, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [42] Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
    Barbera, Joan Albert
    Galie, Nazzareno
    Frost, Adaani
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Mclaughlin, Vallerie
    Peacock, Andrew
    Simonneau, Gerald
    Vachiery, Jean-Luc
    Blair, Christiana
    Miller, Karen
    Harris, Julia
    Langley, Jonathan
    Rubin, Lewis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [43] Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data
    Thoreau, Benjamin
    Mouthon, Luc
    AUTOIMMUNITY REVIEWS, 2024, 23 (04)
  • [44] METHAMPHETAMINE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (MA-PAH): A COHORT STUDY ASSESSING CLINICAL FEATURES AND OUTCOMES AT A TERTIARY CARE CENTER IN ARKANSAS
    Seth, Rohan
    Khrais, Mohammad
    Brewer, Shannon
    Rao, Aarthi
    Atchley, William
    CHEST, 2024, 166 (04) : 5987A - 5988A
  • [45] Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension"
    Chazova, I. E.
    Martynyuk, T. V.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (03) : 114 - 116
  • [46] Identification of pulmonary arterial hypertension (PAH) cases in automated claims data: A pilot study
    Oliveria, Susan A.
    Primatesta, Paola
    Yood, Marianne Ulcickas
    Wei, Feifei
    Robinson, Scott
    Wells, Karen
    Cajigas, Hector
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S243 - S243
  • [47] Clinical Characteristics and Predictors of Methamphetamine-Associated Pulmonary Arterial Hypertension Among Methamphetamine Users Within the University of Kansas Health System
    Cook, C. M.
    Shi, X.
    Dhillon, N. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [48] Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)
    Jiang, Yuxuan
    Turk, Matthew A.
    Pope, Janet E.
    AUTOIMMUNITY REVIEWS, 2020, 19 (09)
  • [49] PHYSICAL THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): RESULTS FROM A GERMAN CLAIMS DATA ANALYSIS
    Barthuber, L.
    Nill, I
    Jacob, C.
    Schmid, T.
    VALUE IN HEALTH, 2024, 27 (12) : S334 - S334
  • [50] Treatment and survival in patients with pulmonary arterial hypertension (PAH)
    Kremers, Hilal Maradit
    Slusser, Joshua P.
    Scott, Christopher G.
    Primatesta, Paola
    McGoon, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S25 - S25